LFVN Lifevantage Corp Insider Trading

Director Lewis Darwin buys 1,055 shares of LFVN at $5.23; stock down -72.7% from 52-week high.

Lewis Darwin purchased 1,055 shares at $5.23 on 2026-03-16, a modest increment to his 136.6K-share position. The transaction occurred as LFVN trades at $4.65, down -72.7% from its 52-week high of $17.04 and down -25.7% over the past 90 days. Notably, Darwin's prior five purchases at LFVN have all been poorly timed: none of the four measurable 90-day outcomes showed positive returns, ranging from -8.3% to -40.6%. This current purchase extends a pattern of unfavorable timing at this specific ticker. While the company reports $48.9M in quarterly revenue with +14.2% annual growth and a low P/E of 7.62, Darwin's repeated purchasing into weakness without subsequent recoveries remains a material observation for assessing insider confidence versus execution timing at this stock.

Dayton Judd (Director) bought 33,197 shares at $4.59 blended average, raising stake to 80,359 shares (+70.4%)

Dayton Judd made 3 separate purchases across three trading days totaling 33,197 shares for $152,422.11, executed at prices ($4.58, $4.63, $4.53) all near the current price of $4.52, which is down 74.3% from the 52-week high of $17.58. His stake in Lifevantage increased 70.4% on a pre-transaction base of 47,162 shares. His prior trade history at LFVN (3 buys in August 2023) each showed positive 90-day returns (+39.9%, +43.8%, +45.4%), and his cross-ticker track record across 3 prior buys averaged +16.3% 90-day returns with a 100.00% win rate. The combination of a substantial open-market accumulation, extreme price decline from recent highs, sustained revenue growth (+14.2% annual), and a director's repeated prior timing success at this ticker warrants close monitoring of subsequent stock performance and any forward guidance.

Director Lewis Darwin buys 3,955 shares of LFVN at $5.22 as stock trades -75.4% from 52-week high.

Lewis Darwin purchased 3,955 shares at $5.22 on 2026-02-09, increasing his holdings from 131,553 to 135,508 shares (+3.0%). The transaction occurs amid significant price deterioration: LFVN currently trades at $5.09, down 25.0% over the past 30 days and -75.4% from its 52-week high of $20.72. His prior purchases at this ticker show mixed timing outcomes—of 5 previous buys, only 1 produced a positive 90-day return, with his most recent purchase (2025-12-15) showing -6.7% over 30 days. The company's fundamentals remain modest but stable: $48.9M in latest-quarter revenue, positive net income of $276.0K, and 14.2% annual revenue growth, valuing the firm at $65.1M with a P/E of 8.34. The transaction signals continued accumulation despite negative momentum and his history of poorly-timed purchases at this ticker.

Director Lewis Darwin buys 805 shares of LFVN at $6.54; stock down -75.1% from 52-week high.

Lewis Darwin (Director) purchased 805 shares at $6.54 on 2025-12-15, increasing his holdings to 131,553 shares. The current stock price of $6.37 is -75.1% from the 52-week high of $25.62, and Darwin's prior purchases at LFVN show a mixed record: only 2 of 5 prior trades achieved positive 90-day returns, with his most recent LFVN purchase on 2025-09-16 declining -40.6% over 90 days. However, his cross-ticker track record shows a 71.43% 90-day win rate with an average 90-day return of +12.1%, suggesting strength in his broader stock-picking discipline despite this ticker's recent underperformance. The company's fundamentals remain modest but solid—$47.6M quarterly revenue, +14.2% annual growth, and a P/E of 7.96—which provides some valuation support near current levels.

Director Lewis Darwin bought 450 LFVN shares at $10.85; stock down 57.5% from 52-week high, 30-day pullback of 16.7%.

Lewis Darwin purchased 450 shares at $10.85 on 2025-09-16, adding to a $117.2K-share position in Lifevantage. The stock is trading at $10.90, significantly depressed from its 52-week high of $25.62 and down 16.7% over the past 30 days. While Darwin's cross-ticker track record shows 13 prior buys with a 76.92% 90-day win rate averaging +16.2% gains, his prior trades at LFVN tell a mixed story: 3 of 5 prior purchases achieved positive 90-day returns (most recently +59.9% and +61.1% in September 2024), but his two June 2025 purchases at this same ticker declined 6.0%–8.9% over 90 days. Fundamentally, the company generated $58.4M revenue and $3.5M net income in the latest quarter with 14.2% annual revenue growth and a low 8.65 P/E, leaving the signal ambiguous between genuine opportunity recognition and accumulation during a prolonged downturn.

Director Lewis Darwin bought 379 shares at blended $12.86 at LFVN; stock down 50.4% from 52-week high, yet 5 of 5 prior same-ticker buys yielded positive 90d returns.

Lewis Darwin, a director at Lifevantage Corp, executed 2 purchases totaling 379 shares for $4,873.18 on 2025-06-13 at a blended average price of $12.86. This acquisition increased his holdings from 116,388 shares to 116,767 shares (+0.3% relative increase). The current stock price of $12.70 sits near the transaction price, but the broader context reveals a significant drawdown: the stock is -50.4% from its 52-week high of $25.62 and has declined -22.0% over the past 90 days. Critically, Darwin's same-ticker buy track record shows a perfect 5 of 5 prior buys at LFVN were well-timed on the 90-day horizon (ranges: 30d returns from -17.3% to +53.1%, but 90d returns all positive from +6.4% to +61.1%), suggesting his entry points have consistently preceded price recoveries at this specific holding. This transaction maintains that disciplined pattern even amid material recent weakness in the stock.

Director Mauro Garry Paul buys 2,150 shares ($26.3K) at $12.25 on 2025-05-09, adding 48.3% to holdings amid -37.4% 90-day decline.

Mauro Garry Paul executed 7 separate purchases totaling 2,150 shares for $26,337.50, expanding his position from 4,448 to 6,598 shares—a 48.3% increase. The transaction occurred at $12.25 per share while the stock has declined 37.4% over the past 90 days and is trading 52.6% below its 52-week high of $25.62. Notably, Paul's prior five trades at LFVN (all buy orders on 2024-09-03) each realized +106.4% returns within 90 days, demonstrating a historically precise pattern of buy timing at this ticker. His cross-ticker track record shows 20 prior buys with a 75% win rate and +38.3% average 90-day return, though current fundamentals show annual revenue declining 6.2% year-over-year with a P/E of 16.62. The director's accumulation during a significant drawdown, combined with his prior successful timing history at this specific company, merits close observation of near-term price action and any catalysts that might explain the recent weakness.

Director Lewis Darwin buys 227 shares of LFVN at $16.00; prior 5 trades at this ticker all well-timed at 90-day mark (+6.7% to +61.1%).

Lewis Darwin, a director, purchased 227 shares at $16.00 on 2024-12-16, a modest increment to his 116.2K share position. His timing pattern at LFVN is notable: across 5 prior open-market buys at this ticker (dating back to March 2024), all were well-timed at the 90-day horizon, with returns ranging from +6.7% to +61.1%, suggesting consistent ability to identify entry points before subsequent appreciation. The stock has already advanced +20.0% in 30 days and +63.7% in 90 days from the transaction date, testing the 52-week high of $16.60 currently. However, valuation context matters: the company carries a P/E of 50.30 against annual revenue decline of -6.2%, creating risk that the current momentum may not sustain. The repetition of timely entries at LFVN merits observation, though the modest share increment and elevated multiples warrant investor scrutiny of whether recent price strength reflects durable fundamentals or stretched valuation.

Director Lewis Darwin buys 351 shares at $10.31 blended avg; extends 5-of-5 pattern of well-timed LFVN purchases (90-day avg +14.4%)

Lewis Darwin (Director) executed 2 separate purchases totaling 351 shares for $3,618.39, bringing his holdings to 108,342 shares (+0.3% increase). His prior 5 open-market buys at LFVN all showed positive 90-day returns—ranging from +1.7% to +32.5%—demonstrating a consistent pattern of purchasing near local lows. The stock has already appreciated 24.5% over the past 30 days and 49.5% over 90 days from prior levels, suggesting this transaction occurs after meaningful recent momentum. With fundamentals showing $48.2M quarterly revenue, $1.7M net income, but a contracting -6.2% annual revenue growth rate and an elevated 31.25 P/E, the purchase adds signal within the context of his documented execution history at this ticker, though the high multiple and negative revenue trajectory warrant investor scrutiny of underlying business momentum versus price momentum.

Director Mauro Garry Paul bought 1,600 shares at $7.40 on 2024-09-03, raising stake 32.4% to 6,539 shares.

Mauro Garry Paul, a director, executed 5 separate purchases totaling 1,600 shares for $11,848.00 at $7.40 per share on 2024-09-03. This transaction increased his holdings by 32.4%, from 4,939 to 6,539 shares. His prior five buys at Lifevantage were executed on 2024-02-02 and 2023-11-16, with all 5 prior trades achieving positive 90-day returns (ranging from 7.0% to 35.4%), indicating a consistent pattern of well-timed entry points at this ticker. The stock currently trades at $9.00 (the 52-week high), having gained 21.8% over 30 days and 17.0% over 90 days. At fundamentals, the company reports $48.2M in quarterly revenue with $1.7M net income, though annual revenue growth is negative at -6.2% year-over-year. The combined signal—a material accumulation at $7.40, strong recent price momentum, and the insider's track record of well-timed purchases at this ticker—merits investor attention.